Cellint Bio

Company Overview

Snapshot

Founded in January 2025 by Matan Hershko and Linur Yeter, Cellint Bio operates with 1–10 employees. The company has secured funding across one round from 4 investors. In April 2026, Cellint Bio received Seed funding from investors including.

Business overview

Cellint Bio develops a fully automated cell-culture R&D platform designed for researchers conducting cell-based biological experiments. The system integrates hardware, mechanics, software, and AI to function within standard incubators, enabling remote monitoring of cell-culture workflows, data visualization, and the generation of predictive insights. This technology aims to minimize manual handling, reduce contamination risks, and decrease execution errors in biological research, serving the Health Tech & Life Sciences sector, particularly in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

When was Cellint Bio founded?

Cellint Bio was founded in January 2025 by Matan Hershko and Linur Yeter.

What is Cellint Bio's primary focus?

Cellint Bio provides a fully automated cell-culture R&D platform for biological researchers, combining hardware, software, and AI to streamline cell-based experiments.

Which investors participated in Cellint Bio's Seed funding round?

In April 2026, Cellint Bio received Seed funding from investors including.

What problem does Cellint Bio's technology address?

Cellint Bio's platform aims to reduce manual handling, contamination risk, and execution errors in cell-culture workflows by providing automated monitoring and predictive insights for researchers.

What sector does Cellint Bio operate in?

Cellint Bio operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.